Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Jorge Sierra, MD, Pau Montesinos, MD PhD, Xavier Thomas, MD PhD, Laimonas Griškevičius, MD PhD, Thomas Cluzeau, MD PhD, Denis Caillot, Ollivier Legrand, MD, Clara Minotti, MD, Mario Luppi, Firas Farkas, MD, Bourras-Rezki Bengoudifa, MS, Geralyn Gilotti, MSc, Sejla Hodzic, MD, Alessandro Rambaldi, MD PhD, Adriano Venditti, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136083

Published: 2020

Journal Articles

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Serena Rosati, MD, Massimo Breccia, MD, Carmelo Gurnari, MD, Ida Carmosino, Emilia Scalzulli, MD, Enrico Montefusco, Salvatore Perrone, MD, Ombretta Annibali, Vincenza Martini, MD, Giulio Trapè, Malgorzata Monika Trawinska, MD, Clara Minotti, MD, Giuseppe Cimino, MD, Agostino Tafuri, MD, Giuseppe Avvisati, MD, Maria Teresa Voso, MD, Robin Foà, MD, Roberto Latagliata

Blood (2019) 134 (Supplement_1): 3845.

https://doi.org/10.1182/blood-2019-129216

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 3687.

https://doi.org/10.1182/blood.V124.21.3687.3687

Published: 2014

Journal Articles

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Blood (2014) 124 (21): 5326.

https://doi.org/10.1182/blood.V124.21.5326.5326

Published: 2014

Journal Articles

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Blood (2014) 124 (21): 1063.

https://doi.org/10.1182/blood.V124.21.1063.1063

Published: 2014

Journal Articles

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols

Massimo Breccia, Luca Mazzarella, Vincenzo Bagnardi, Davide Disalvatore, Giuseppina Loglisci, Giuseppe Cimino, Anna Maria Testi, Giuseppe Avvisati, Maria Concetta Petti, Clara Minotti, Roberto Latagliata, Robin Foà, Pier Giuseppe Pelicci, Francesco Lo-Coco

Blood (2012) 119 (1): 49–54.

https://doi.org/10.1182/blood-2011-07-369595

Published: 2012

Journal Articles

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.

Paola Finsinger, Massimo Breccia, Clara Minotti, Ida Carmosino, Laura Cannella, Paola Volpicelli, Federico Vozella, Caterina Stefanizzi, Giuseppina Loglisci, Giuseppe Cimino, Robin Foà, Roberto Latagliata, MD

Blood (2009) 114 (22): 4160.

https://doi.org/10.1182/blood.V114.22.4160.4160

Published: 2009

Journal Articles

Fludarabine, Ara-C, Novantrone and Dexamethasone Plus Campath-1H for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) and Adverse Clinical and Biologic Prognostic Features.

Francesca R. Mauro, MD, Elena Giammartini, MD, Maria S. De Propris, BD, Giuseppe Gentile, MD, Mauro Nanni, BD, Emanuela M. Ghia, BD, Irene Della Starza, BD, Ilaria Del Giudice, MD, Simona Santangelo, BD, Marilisa Marinelli, BD, Fulvia Brugnoletti, MD, Clara Minotti, MD, Vera Capria, MD, Anna Guarini, BD, Robert Foa, MD

Blood (2006) 108 (11): 2830.

https://doi.org/10.1182/blood.V108.11.2830.2830

Published: 2006

NARROW

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects

Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.

Fludarabine, Ara-C, Novantrone and Dexamethasone Plus Campath-1H for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) and Adverse Clinical and Biologic Prognostic Features.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only